Drugs / CYAD-211
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04613557 | Nov 2020 → Dec 2022 overdue | refractory plasma cell neoplasm | Celyad Oncology SA | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYAD-211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04613557 ↗ |
| Modality | Cell therapy | “allogeneic CYAD-211 (anti-BCMA CAR-T) cells” NCT04613557 ↗ |